Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Basic) (2017 - 2025)

UroGen Pharma's EPS (Basic) history spans 9 years, with the latest figure at -$0.53 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 33.75% year-over-year to -$0.53; the TTM value through Dec 2025 reached -$3.19, down 6.33%, while the annual FY2025 figure was -$3.19, 7.77% down from the prior year.
  • EPS (Basic) reached -$0.53 in Q4 2025 per URGN's latest filing, up from -$0.69 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.51 in Q3 2024 to a low of -$1.35 in Q3 2021.
  • Average EPS (Basic) over 5 years is -$0.98, with a median of -$1.04 recorded in 2023.
  • Peak YoY movement for EPS (Basic): skyrocketed 42.4% in 2023, then crashed 35.29% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$1.27 in 2021, then rose by 1.57% to -$1.25 in 2022, then surged by 42.4% to -$0.72 in 2023, then dropped by 11.11% to -$0.8 in 2024, then skyrocketed by 33.75% to -$0.53 in 2025.
  • Per Business Quant, the three most recent readings for URGN's EPS (Basic) are -$0.53 (Q4 2025), -$0.69 (Q3 2025), and -$1.05 (Q2 2025).